ArticleJournal of hepatocellular carcinoma2025
Predictive Value of IDEAL-IQ and DWI Imaging Biomarkers for P53 Mutations in Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An MRI-Based Intratumoral and Peritumoral 2.5D Deep Learning Model for Predicting P53-Mutated Hepatocellular Carcinoma: A Two-Center Study.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the application of imaging biomarkers, including R2*, Fat Fraction (FF) and apparent diffusion coefficient (ADC) values, obtained through Iterative Decomposition of water and fat with Echo Asymmetry and Least-squares estimation for Imaging Quantification (IDEAL-IQ) and DWI techniques, in differentiating P53-mutated and non-mutated HCC. Patients and Methods: This retrospective study included patients with pathologically confirmed HCC between January 2019 and July 2024. HCC were divided into P53-mutated group and non-mutated group by immunostaining. Preoperative R2*, FF, and ADC values derived from IDEAL-IQ and DWI were compared between the two groups, as well as different histological grades. Receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic performance of each MRI parameter for detecting P53 mutations in HCC, with area under the curve (AUC) compared by Delong's test. Results: Compared to the non-mutated group, the P53-mutated group (n = 31) showed significantly higher R2* values (34.821 ± 9.980 vs 23.713 ± 5.586, P < 0.001) and lower ADC values (0.760 ± 0.142 vs 0.855 ± 0.130, P = 0.002), while FF values showed no significant difference (P = 0.646). R2*, ADC, and the combined model (R2* + ADC) revealed AUCs of 0.849, 0.726, and 0.856, respectively, with the combined model demonstrating the highest sensitivity and specificity. Additionally, high-grade HCC showed significantly lower ADC values compared to lower-grade tumors (P < 0.001). Conclusion: R2* and ADC exhibited significant features in P53-mutated HCC, suggesting their potential as non-invasive biomarkers for predicting P53 mutation status and guiding clinical management. The combined use of R2* and ADC may further enhance diagnostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.